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Abstract
Aims/hypothesis Biological ageing of the immune system, or
immunosenescence, predicts poor health and increased mor-
tality. A hallmark of immunosenescence is the accumulation
of differentiated cytotoxic T cells (CD27−CD45RA+/−; or
dCTLs), partially driven by infection with the cytomegalovi-
rus (CMV). Immune impairments reminiscent of
immunosenescence are also observed in hyperglycaemia,
and in vitro studies have illustrated mechanisms by which
elevated glucose can lead to increased dCTLs. This study
explored associations between glucose dysregulation and
markers of immunosenescence in CMV+ and CMV−
individuals.
Methods A cross-sectional sample of participants from an oc-
cupational cohort study (n=1,103, mean age 40 years, 88%
male) were assessed for HbA1c and fasting glucose levels,
diabetes, cardiovascular risk factors (e.g. lipids), numbers of
circulating effector memory (EM; CD27−CD45RA−) and
CD45RA re-expressing effector memory (EMRA;
CD27−CD45RA+) T cells, and CMV infection status. Self-
report and physical examination assessed anthropometric,
sociodemographic and lifestyle factors.
Results Among CMV+ individuals (n=400), elevated HbA1c
was associated with increased numbers of EM (B=2.75,
p<0.01) and EMRA (B=2.90, p<0.01) T cells, which was
robust to adjustment for age, sex, sociodemographic variables
and lifestyle factors. Elevated EM T cells were also positively
associated with total cholesterol (B=0.04, p<0.05) after ap-
plying similar adjustments. No associations were observed in
CMV− individuals.
Conclusions/interpretation The present study identified con-
sistent associations of unfavourable glucose and lipid profiles
with accumulation of dCTLs in CMV+ individuals. These
results provide evidence that the impact of metabolic risk fac-
tors on immunity and health can be co-determined by infec-
tious factors, and provide a novel pathway linking metabolic
risk factors with accelerated immunosenescence.
Keywords Cholesterol . CMV . Cytomegalovirus .
Diabetes . Glucose . Haemoglobin A1c . HbA1c . Immune
ageing .Metabolic syndrome . Tcell
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Introduction
The progressive impairment of immunity with age, known as
immunosenescence, is thought to underlie increased infection
risk and mortality [1, 2] and may also contribute to several
other age-associated complications, including low-grade in-
flammation and increased cardiovascular disease (CVD) risk
[3–5]. Infection with cytomegalovirus (CMV) has been
shown to accelerate features of immunosenescence [2, 6–8].
This herpes virus establishes a lifelong latent infection,
interrupted by periods of non-clinical reactivation. The resul-
tant activation of CMV-specific T cells leads to a marked
accumulation of differentiated cytotoxic T cells (dCTLs;
CD27−CD45RA+/−), which can be subdivided into effector
memory (EM; CD27−CD45RA−) T cells and CD45RA re-
expressing EM T cells (EMRA; CD27−CD45RA+) [6, 9].
Indeed, infected (i.e. CMV+) individuals have on average
three- to fourfold higher dCTL numbers compared with unin-
fected (i.e. CMV−) individuals, although large inter-individual
differences exist [10].
The accumulation of dCTLs may make a material contri-
bution to the acceleration of immunosenescence [11] and is
thought to provide a mechanism through which
immunosenescence may be associated with health outcomes,
such as CVD [12]. For example, these T cells show a high
production of proinflammatory cytokines, have short telo-
meres and have an aberrant proliferative capacity [13, 14].
Thus, the accumulation of dCTLs may be the mechanism
linking CMV with the hallmarks of immune ageing.
Significantly, many of the immune system impairments
that have been associated with ageing resemble those of
chronic hyperglycaemia. For example, impaired glucose tol-
erance and diabetes are associated with poor control of infec-
tion [15–17], impaired vaccination responses [18], elevated
inflammatory activity [19] and shorter leucocyte telomere
length [4, 20]. These observations raise the question of wheth-
er the immune effects of hyperglycaemia may, at least in part,
involve the accumulation of dCTLs [21]. For example, in vitro
studies show that strong T cell stimulation – similar to that
which might be elicited by CMV reactivation – enhances cel-
lular glucose uptake, which can lead to the accumulation of
readily activated memory T cells that acquire resistance to cell
death [22]. This presents a potential mechanism whereby
hyperglycaemia may amplify the CMV-induced accumulation
of dCTLs.
Therefore, the aim of the current study was to examine the
relationship between glucose metabolism (i.e. HbA1c and
fasting glucose levels and diabetic status) and EM and
EMRA T cell numbers in a large sample of CMV+ and
CMV− individuals. It was hypothesised that the effects of
CMV infection on dCTL numbers would be enhanced in
CMV+ individuals that show evidence of elevated glucose.
Additionally, other factors associated with hyperglycaemia
that may contribute to increased dCTL accumulation were
also examined, including markers of dyslipidaemia (i.e. ele-
vated circulating triacylglycerol and LDL-cholesterol
[LDL-C], and lower HDL-cholesterol [HDL-C]) and elements
of the metabolic syndrome [23].
Methods
Participants The present study was conducted among em-
ployees (n=1,103; 88% male; mean age 40 years [range 18–
64 years]) of a large European airplane manufacturer in the
south of Germany who took part in a voluntary company
health check in 2011. Participant characteristics are presented
in Table 1. Participants received a personalised comprehen-
sive health report. All data were anonymised before analysis.
This study was approved by the ethics committee of the
Medical Faculty Mannheim, Heidelberg University. All par-
ticipants gave written informed consent.
Procedures Participants arrived at a location away from their
usual workplace between 06:45 and 08:45 hours in the morn-
ing for their health check. After drawing fasting venous blood
and a medical examination, participants were seated in a quiet
room to fill out questionnaires on demographic, medical and
health behaviour data. Anthropometric (e.g. height, weight,
waist and hip circumference) and BP measurements were car-
ried out by trained study personnel. Demographic data, in-
cluding age, sex and marital status, along with socioeconomic
status (SES) indicators (measured as hierarchical job position,
manual occupation and shift work), self- and doctor-
diagnosed medical conditions, and lifestyle factors (e.g.
smoking, alcohol intake, exercise) were obtained by question-
naires used and validated in theMONICA (‘Monitoring trends
and determinants in cardiovascular disease’) study [24].
Flow cytometry T cell phenotypes were assessed by flow
cytometry. Whole blood samples were collected in EDTA-
coated tubes (Sarstedt, Nümbrecht, Germany), stored at room
temperature and prepared within 1 h of collection. Briefly,
30 μl whole blood was stained with a combination of the
following conjugated monoclonal antibodies: anti-CD3
allophycocyanin (APC)–cyanine dye 7 (Cy7; clone SK7),
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anti-CD4–peridinin chlorophyll protein (clone SK3), anti-γδ
T cell receptor (γδTCR)–phycoerythrin (PE; clone B1), anti-
CD8–APC (clone SK1; BD Biosciences, San José, CA,
USA); and anti-CD45RA–FITC (clone HI100) and anti-
CD27–PE-Cy7 (clone M-T271; BD Pharmingen, San Diego,
CA). All antibodies were purchased from and validated by BD
Biosciences and BD Pharmingen at pre-diluted concentrations
for use at the recommended volume per test. Following a
20 min incubation at room temperature in the dark, 1.5 ml
BD FACS lysing solution (BD Biosciences) was added to
the mixture and incubated for another 15 min. After centrifu-
gation for 7 min at 700g, the supernatant was removed and
both lysed erythrocytes and unbound antibody were washed
away. The pellet was subsequently re-suspended in 250 μl 2%
paraformaldehyde solution until analysis. Data were collected
using a FACSCanto II flow cytometer and dedicated
FACSDiva software (BD Biosciences). Spectral overlap was
electronically compensated for using single labelled antibody
tubes. Following data acquisition, files were transferred to a
third party software program (FlowJo v7.6.5, Tree Star,
Ashland, OR, USA) for analysis. Representative plots of the
gating strategy are shown in electronic supplementary materi-
al Fig. 1. Lymphocyte numbers were obtained by multiplying
the total leucocyte count by the percentage of gated lympho-
cytes. The lymphocyte number was further multiplied by the
percentages of gated CD3+ cells and their subsequent subsets
to calculate the numbers of cells per microlitre used in the
analyses.
CMV status determination Fasting plasma samples were
stored in small aliquots at −80°C until analysis. Evidence of
a previous CMVinfection (serostatus) was determined using a
commercially available ELISA (BioCheck, Foster City, CA,
USA) according to the manufacturer’s instructions. Optical
density values obtained from participants’ samples were fitted
to a standard curve. These concentrations were then compared
with a cut-off value to compute CMV index scores.
Participants with a borderline seropositive result, i.e. a calcu-
lated index score of >0.85 and <1.15, were re-tested (n=9). If
they remained borderline, participants with index scores
Table 1 Participant sociodemographic and lifestyle characteristics
Characteristic Total CMV status p value
Positive Negative
n (%) 1,103 400 (36) 703 (64)
Age (years) 40.1±11.0 41.5±11.1 39.3±10.8 <0.001
Sex (% male) 87.7 84.5 89.5 0.020
Married/co-habiting (%) 77.0 80.4 75.0 0.065
Job status (%) – – – 0.007
Division/dept mgr 4.8 3.5 5.6 –
Project leader/process mgr 15.3 13.9 16.2 –
Worker (mgrl) 6.7 6.0 7.1 –
Skilled worker (non-mgrl) 63.8 62.6 64.4 –
Semi-skilled worker 9.4 14.1 6.7 –
Shift worker (% yes) 28.1 33.8 24.9 0.003
Manual occupation (% yes) 49.6 55.0 46.5 0.008
Smoking (%) – – – 0.050
Never smoker 46.1 41.1 48.9 –
Former smoker 24.9 27.0 23.8 –
Smoker 29.0 31.9 27.3 –
Cigarettes per day (in smokers) 14±8 15±7 13±8 0.090
Alcohol (%) – – – <0.001
0–2 times/month 24.9 30.4 21.7 –
1–2 times/week 29.9 32.5 28.5 –
3–7 times/week 45.2 37.2 49.8 –
Leisure physical activity (h/week) 7.0±7.5 7.1±9.4 7.0±6.2 0.307
Data are unadjusted comparisons of participant characteristics: a Student’s t test was performed for continuous variables and a χ2 test for categorical
variables
Data are means±SD unless otherwise stated
Dept, department; mgr, manager; mgrl, managerial
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above and below 1.00 were considered CMV+ and CMV−,
respectively, as per the manufacturer’s instructions. The sen-
sitivity, specificity and accuracy of the test are reported as
95.0%, 96.7% and 96.0%, respectively.
Biochemical analysisHbA1c, fasting glucose, triacylglycerol,
LDL-C, HDL-C and high-sensitivity C-reactive protein levels
were measured by an accredited clinical laboratory (Synlab
Laboratories, Augsburg, Germany) according to standard lab-
oratory procedures that comply with International
Organization for Standardization norms (DIN EN ISO
15189). HbA1c levels were measured using a second-
generation HbA1c immunoassay (Roche Diagnostics,
Mannheim, Germany), and fasting glucose levels were mea-
sured using the glucose hexokinase enzymatic assay (Glucose
OSR6121, Beckman Coulter, Brea, CA, USA), in accordance
with the latest standardised guidelines and recommendations
for laboratory analysis in the diagnosis of diabetes [25].
Cholesterol and triacylglycerol were automatically measured
enzymatically (Cobas 8000 analyser; Roche Diagnostics).
HDL-C was measured using a competitive homogeneous as-
say (Roche Diagnostics), and LDL-Cwas calculated using the
Friedewald equation [26]. These values were also used to
calculate the ratio of LDL-C to HDL-C.
Diabetes and metabolic syndrome classification Diabetes
was classified according to the ADA guidelines in individuals
with fasting glucose levels of >6.94 mmol/l and/or HbA1c
levels of ≥6.5% (48 mmol/mol) in the absence of known dia-
betes. Those with self-reported, doctor-diagnosed diabetes
were also classified as diabetic. Prediabetes was classified as
a fasting glucose level between 5.55 and 6.94 mmol/l and/or
an HbA1c level between 5.7% (39 mmol/mol) and 6.4%
(46 mmol/mol) [27]. The remaining normal-glycaemic indi-
viduals, therefore, had fasting glucose and HbA1c levels of
<5.55 mmol/l and <5.7%, respectively. The metabolic syn-
drome components were assessed as the following: (1) waist
circumference >102 cm (men) or >88 cm (women); (2) plas-
ma triacylglycerol >1.70 mmol/l; (3) plasma HDL-C
<1.03 mmol/l (men) or <1.29 mmol/l (women); (4) BP
≥130 mmHg (systolic) and/or ≥85 (diastolic) mmHg; and (5)
plasma fasted glucose ≥5.55 mmol/l. Each of these compo-
nents were dichotomised (yes or no) and added together to
create a metabolic syndrome component score (range 0–5).
Those with a score of ≥3 were classified as having the meta-
bolic syndrome [28].
Statistical analysis To approximate a normal distribution of
the variables used in the current analyses, we applied transfor-
mations based on information criteria obtained from the
Ladder-of-Powers in Stata 12 (StataCorp, College Station,
TX, USA). The transformation with the least statistical devi-
ation from a normal distribution, indicated by the smallest χ2
(or the most non-significant p value) was used, as previ-
ously recommended [29]. Missing data (<7% for all var-
iables) was handled by multiple imputation in IBM SPSS
(version 20, Chicago, IL, USA). Briefly, a fully condition-
al specification method was automatically chosen to re-
place missing data. In this method, each variable was
fitted in a univariate (single dependent variable) model
using all other available variables in the model as predic-
tors, and missing values were imputed for each variable
being fitted. Linear and logistic regressions were used for
continuous and categorical variables, respectively.
Relevant variables with already complete data were en-
tered only as predictors to improve estimates. After ten
iterations for each of the five imputation datasets, pooled
estimates were used for all subsequent analyses below.
First, participant characteristics (i.e. demographics and life-
style behaviours) were compared between CMV+ and CMV−
individuals. Student’s t tests and χ2 analyses were used for
continuous and categorical variables, respectively.
Second, differences in CMV status by HbA1c and fasting
glucose levels and diabetic status were explored using binary
logistic regressions. CMV status was entered as the dependent
variable, and each factor was entered, in turn, as an indepen-
dent variable. Potential confounders known to impact CMV
infection and reactivation, including age, sex, marital status,
SES (job status, manual occupation), and lifestyle factors
(smoking, alcohol intake, BMI, and physical activity)
[30–32], were statistically controlled in hierarchical models
(Models 1–3): Model 1 was adjusted for age and sex; Model
2 was Model 1 additionally adjusted for marital status and
SES (job status and manual occupation); and Model 3 was
Model 2 further adjusted for smoking, alcohol, BMI and phys-
ical activity. Thesemodels were entered stepwise as covariates
throughout the remaining analyses.
Third, numbers of CD8+ EM and EMRATcells were com-
pared between levels of glycaemic control (indicated by dia-
betic classification) using ANOVA and ANCOVA. These
analyses were st rat i f ied by CMV status and the
abovementioned potential confounders were entered as covar-
iates (Models 1–3).
Finally, separate linear regressions were used to explore the
individual associations of HbA1c and fasting glucose levels
with EM and EMRA T cell subset numbers. Potential con-
founders were entered as covariates using the same models
as above.
The above analyses were repeated with each of the
dyslipidaemia and CVD risk factors (i.e. total cholesterol,
LDL-C, HDL-C, the LDL-C to HDL-C ratio and triacylglyc-
erol) entered separately as independent predictors of EM and
EMRA T cell subset numbers. For significant associations,
HbA1c was added as a potential mediator to examine the role
of glucose levels on lipid metabolism. All analyses were per-
formed with IBM SPSS version 20.
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Results
Participant characteristics As shown in Table 1, 400 of the
1,103 (36.3%) participants were CMV+. On average, CMV+
participants tended to be older and female. They were also
more likely to be current or former smokers, to drink less
frequently, and to have a lower SES (low job status, more
manual occupations and shift work). There was no difference
in the amount of cigarettes smoked (among smokers), BMI,
WHR or physical activity (p>0.10 for all; Table 1). The tab-
ulation of metabolic risk factors revealed that 290 (26.3%)
individuals met the criteria for metabolic syndrome classifica-
tion. Regarding diabetes, 663 were classified as normal, 404
as prediabetic and 36 as diabetic. Because of the small number
of diabetic individuals, the diabetic group was merged with
the prediabetic group and labelled ‘hyperglycaemic’.
Glycaemic control and dyslipidaemia factors are associat-
ed with CMV infection Unadjusted analyses showed that
CMV+ individuals were more likely to have higher levels of
HbA1c (38.1 vs 37.7 mmol/mol) and to be classified as
hyperglycaemic, i.e. prediabetic or diabetic (46.2% vs
36.4%; Table 2). In binary logistic regressions, the associa-
tions of HbA1c and hyperglycaemic status with CMV infec-
tion status were reduced to non-significance after adjusting for
age and sex (Model 1) and sociodemographic factors (Model
2), respectively.
Unadjusted comparisons of dyslipidaemia factors between
CMV+ and CMV− individuals revealed that CMV+ individuals
were also more likely to have HDL-C levels that fell within the
metabolic syndrome classification range (men <1.03 mmol/l,
women <1.29 mmol/l). However, none of the other metabolic
characteristics, including themetabolic syndrome classification,
differed by CMV status in unadjusted analyses (Table 2). After
progressive adjustment for possible confounders (Models 1–3),
the association with the low HDL-C category was no longer
significant, but increased levels of continuous HDL-C became
significantly associated with CMV infection ((OR 0.55
[95% CI] 0.319–0.960), p=0.035). That is, individuals with
higher HDL-C levels (natural log-transformed) had a lower risk
of CMV infection.
Glycaemic control and its interaction with CMV infection
are associated with dCTL numbers Fig. 1 shows the
Table 2 Participant metabolic
characteristics Characteristic Total CMV status p value
Positive Negative
n (%) 1,103 (100) 400 (36) 703 (64)
HbA1c (%) 5.61±0.01 5.64±0.02 5.60±0.01 0.047
HbA1c (mmol/mol) 37.84±0.11 38.13±0.18 37.67±0.13 0.060
Fasting glucose (mmol/l) 4.82±0.02 4.85±0.03 4.80±0.02 0.168
Total cholesterol (mmol/l) 5.25±0.03 5.28±0.05 5.24±0.04 0.591
LDL-C (mmol/l) 3.20±0.03 3.22±0.04 3.19±0.03 0.580
HDL-C (mmol/l) 1.40±0.01 1.38±0.02 1.41±0.02 0.068
LDL-C/HDL-C ratio 2.47±0.03 2.54±0.05 2.42±0.04 0.140
Triacylglycerol (mmol/l) 1.42±0.03 1.47±0.05 1.39±0.03 0.145
Diabetes classification (%) – – – 0.005
Normal 60.1 53.9 63.6 –
Prediabetes 36.6 41.9 33.7 –
Diabetes 3.3 4.3 2.7 –
Metabolic syndrome (% yes) 26.3 28.0 25.3 0.368
Waist circumference (% yes) 52.1 54.0 51.0 0.387
Triacylglycerol (% yes) 31.8 35.0 30.0 0.101
HDL-C (% yes) 17.7 21.0 15.8 0.036
BP (% yes) 52.5 49.5 54.2 0.150
Fasting glucose (% yes) 10.0 11.0 9.4 0.442
BMI, (kg/m2) 24.46±4.10 24.46±4.13 24.46±3.98 0.929
WHR 0.90±0.08 0.90±0.08 0.90±0.07 0.190
All are unadjusted comparisons of participant metabolic characteristics: a Student’s t test was performed for
continuous variables and a χ2 test for categorical variables. HDL-C is natural log-transformed, LDL-C is square
root-transformed and total cholesterol is square root-transformed
Values are means±SD unless otherwise stated
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unadjusted comparisons of EM and EMRA T cell numbers
stratified by glycaemic status and CMV infection. For all par-
ticipants, individuals classified as hyperglycaemic had 26.6%
higher numbers of EM (110.2 vs 87.0 cells/μl) and 41.2%
higher EMRA T cells (218.1 vs 154.5 cells/μl; both
p<0.001) than normoglycaemic participants.
When further stratified by CMV status, the results showed
significantly more EMRA T cells in hyperglycaemic vs
normoglycaemic CMV+ individuals (p<0.001), while no such
difference was observed in the CMV− group (Fig. 1). This
effect remained significant after full adjustment, and was ac-
companied by a significant interaction of CMV status by
glycaemic status with EMRA levels (p=0.031). In addition,
these effects did not appear to be caused by the small group of
diabetic individuals because identical results were found when
diabetic participants were excluded from the analyses (data
not shown). Analyses adjusted for age and sex showed that
there were more EM T cells in hyperglycaemic individuals
than in the normoglycaemic group, but this did not reach
significance.
Increased HbA1c is associated with increased dCTL num-
bers Table 3 shows the linear associations ofmetabolic factors
with dCTL numbers. Overall, higher levels of continuous
HbA1c were associated with increased numbers of dCTLs
(EM: B=1.87, p<0.001; EMRA: B=2.05, p<0.01) after ad-
justment for age, sex, marital status and SES (i.e. job status
and manual occupation; Model 2). These associations
remained significant after additional adjustment for lifestyle
factors (Model 3; both p<0.05). The fasting glucose level was
nonsignificantly associated with dCTL numbers in the overall
sample (Table 3). When analyses were stratified by CMV
status, the relationship between HbA1c and increased dCTL
numbers remained in CMV+, but not in CMV− individuals
(both p<0.01).
CMV− and HbA1c-related associations between
dyslipidaemia factors and dCTL numbers For all partici-
pants, linear regression showed that higher continuous levels
of triacylglycerol were associated with increased numbers of
dCTLs after adjustment for confounders (Models 1–3;
Table 3). Lower HDL-C levels and a higher LDL-C/HDL-C
ratio were also significantly associated with increased EM and
EMRA numbers after adjustment for sociodemographic fac-
tors (Model 2). Except for the LDL-C/HDL-C association
with EM T cells, these relationships were attenuated by addi-
tional adjustment for lifestyle factors (Model 3). Total choles-
terol and LDL-C levels were nonsignificantly associated with
dCTL numbers in the full sample (Table 3).
When analyses were stratified by CMV status, the relation-
ship between triacylglycerol and increased dCTL numbers
was found only in CMV+ individuals. Additionally, in the
CMV+ group, total cholesterol and the LDL-C/HDL-C ratio
were positively associated with EM T cell numbers after ad-
justment for sociodemographic factors (Model 2; both
p<0.05), although only total cholesterol remained significant
after full adjustment (Model 3; Table 3).
To test the influence of glucose metabolism on the signif-
icant lipid profile associations in CMV+ individuals (i.e. triacyl-
glycerol and cholesterol), HbA1c was additionally entered
into each of these fully adjusted models. After the addition of
HbA1c to the model, the associations between triacylglycerol
and dCTL were attenuated, while the relationship between
cholesterol and EM T cells remained significant (data not
shown). Among CMV− individuals, no significant associations
were observed between any metabolic factors and dCTL
numbers (Table 3).
Discussion
A hallmark of an ageing immune system is the accumulation
of differentiated CD8+ T cells, which is strongly enhanced in
CMV-infected individuals. The present study demonstrated
that impaired glycaemic control, as measured by HbA1c
levels, is associated with elevated numbers of dCTL in
CMV+ individuals, but not in CMV− individuals. This asso-
ciation was robust to adjustment for demographic, SES and
lifestyle factors. Thus, this study is the first to provide evi-
dence that glycaemic control may contr ibute to
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Fig. 1 Unadjusted comparison of (a) EM (CD27−CD45RA−) and (b)
EMRA (CD27−CD45RA+) CD8+ T cell subset numbers by glycaemic
status and CMV infection. White bars, normoglycaemic; black bars,
hyperglycaemic. *p<0.05 and ***p<0.001 represent levels of significant
difference from normoglycaemic. †p<0.001 represents significant differ-
ence from CMV−
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immunosenescence by amplifying the effects of CMV on T
cell differentiation. This mechanism may contribute to the
impaired immunity seen in hyperglycaemia and diabetic pa-
tients, and may possibly be a pathway linking CMV to in-
creased CVD risk.
HbA1c may be positively associated with dCTL in CMV
+
individuals due to a synergistic impact on both the extent of
CMV replication and the T cell response to CMV activity.
Elevated glucose levels may: (1) directly and indirectly in-
crease the efficiency and frequency of CMV replication; and
(2) enhance the T cell responses to CMV. First, CMV-induced
upregulation of GLUT4 enhances glucose uptake [33]. This
excess glucose influx is diverted towards the biosynthesis of
fatty acids, which are used to directly increase viral production
and enhance infectivity [34]. Indirectly, elevated glucose pro-
motes the production of reactive oxygen species, which are
known to stimulate the CMV promoter region and provide the
first step that is necessary, but not sufficient, for the reactiva-
tion of CMV [35, 36]. Second, evidence from in vitro studies
demonstrates that strong, repeated antigen receptor stimula-
tion (e.g. by CMV) can lead to the upregulation of GLUT1
and to enhanced glucose uptake by T cells. Excess glucose
uptake was shown to parallel increased T cell activation, pro-
inflammatory cytokine production and an elevated threshold
for cell death [21, 22]. Although not directly investigated in
the present study, these represent biologically plausible mech-
anisms through which elevated glucose could augment dCTL
numbers via CMVactivity.
Attenuation of the relationship between hyperglycaemia
and CMV infection by sociodemographic factors is in line
with the finding of null associations after similar adjustments
in other studies [37, 38], but is inconsistent with the somewhat
divergent epidemiological data from Chen and colleagues in
very old (85 years) adults [39]. The former finding suggests
Table 3 Unstandardised coefficients from linear regressions of metabolic factors and EM and EMRAT cell numbers
Variables EM (CD27−CD45RA−) EMRA (CD27−CD45RA+)
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
All participants (n=1,103)
HbA1c 2.03 (0.58)*** 1.87 (0.59)*** 1.54 (0.59)* 2.20 (0.77)** 2.05 (0.77)** 1.68 (0.78)*
Fasting glucose 2.15 (2.06) 2.31 (2.06) 3.23 (2.07) −2.92 (2.69) −2.74 (2.70) −1.72 (2.73)
Cholesterol 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.02 (0.01)
LDL-C 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01)
HDL-C −0.13 (0.05)** −0.13 (0.05)** −0.06 (0.05) −0.16 (0.06)** −0.15 (0.06)* −0.08 (0.06)
LDL-C/HDL-C 0.20 (0.07)** 0.20 (0.07)** 0.14 (0.07)* 0.21 (0.09)* 0.21 (0.09)* 0.13 (0.10)
Triacylglycerol 0.14 (0.05)** 0.13 (0.05)** 0.11 (0.05)* 0.21 (0.07)** 0.20 (0.07)** 0.18 (0.07)*
CMV negative (n=703)
HbA1c 0.97 (0.65) 0.86 (0.65) 0.46 (0.66) 0.87 (0.23) 0.94 (0.82) 0.48 (0.84)
Fasting glucose 2.34 (2.18) 2.40 (2.18) 3.75 (2.23) −1.3 (2.77) −1.29 (2.77) 0.36 (2.84)
Cholesterol 0.00 (0.01) 0.00 (0.01) 0.00 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01)
LDL-C 0.00 (0.01) 0.01 (0.01) 0.00 (0.01) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01)
HDL-C −0.09 (0.05) −0.08 (0.05) −0.03 (0.05) −0.02 (0.06) −0.03 (0.06) 0.02 (0.07)
LDL-C/HDL-C 0.11 (0.07) 0.12 (0.07) 0.06 (0.08) 0.08 (0.09) 0.09 (0.09) 0.01 (0.10)
Triacylglycerol 0.07 (0.06) 0.06 (0.06) 0.03 (0.06) 0.12 (0.07) 0.13 (0.07) 0.09 (0.07)
CMV positive (n=400)
HbA1c 3.11 (1.03)** 3.02 (1.03)** 2.75 (1.03)** 3.02 (1.00)** 2.92 (1.01)** 2.90 (1.02)**
Fasting glucose 2.41 (3.82) 2.19 (3.83) 2.36 (3.83) −3.86 (3.72) −3.78 (3.74) −3.40 (3.77)
Cholesterol 0.04 (0.02)* 0.04 (0.02)* 0.04 (0.02)* 0.03 (0.02) 0.03 (0.02) 0.03 (0.02)
LDL-C 0.03 (0.01) 0.03 (0.01) 0.03 (0.01)* 0.02 (0.01) 0.02 (0.01) 0.02 (0.01)
HDL-C −0.11 (0.08) −0.10 (0.08) −0.04 (0.09) −0.11 (0.08) −0.10 (0.08) −0.06 (0.09)
LDL-C/HDL-C 0.27 (0.12)* 0.26 (0.12)* 0.22 (0.13) 0.21 (0.12) 0.22 (0.12) 0.18 (0.13)
Triacylglycerol 0.22 (0.09)* 0.22 (0.09)* 0.20 (0.10)* 0.23 (0.09)* 0.22 (0.09)* 0.21 (0.10)*
Data are unstandardised coefficients (B) (SEM)
Model 1: adjusted for age and sex
Model 2: model 1 with additional adjustment for marital status and SES (job status and manual occupation)
Model 3: model 2 further adjusted for smoking, alcohol, BMI and physical activity
*p<0.05, **p<0.01 and ***p=0.001
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that unadjusted differences in glucose by CMV status are like-
ly to be a consequence of common predisposing factors, rather
than being causally linked. Indeed, both CMV infection and
dysregulated glucose metabolism are more common in indi-
viduals with a variety of pre-existing health risk factors. For
example, CMV has a non-random distribution in the popula-
tion: infection is particularly prevalent among those who are
typically older, current smokers or have low SES (job status,
education) [31, 40]. On the other hand, the robust linear rela-
tionships between HbA1c and both EM and EMRA T cells
found only in CMV+ individuals suggest that glycaemic status
may contribute to immune responses to CMV reactivation
rather than to initial infection.
The current positive relationship between markers of
dyslipidaemia and numbers of dCTLs in CMV+ individuals
appears to be partly a by-product of the intrinsic link between
HbA1c level and lipid metabolism found in both diabetic [23]
and non-diabetic adults [41]. Evidence for this relationship is
provided by the null associations between triacylglycerol and
dCTL numbers in CMV+ individuals after additional adjust-
ment for HbA1c level in the current study. In contrast, the
cholesterol–EM association remained after additional adjust-
ment for HbA1c level, making a more direct effect of CMV
more plausible. The factors underlying this association are not
clear, but could reflect the manifestation of a host defence
mechanism to limit CMV infectivity. At an early stage of
CMV infection, cells increase the expression of CD91, which
regulates lipid metabolism and decreases intracellular choles-
terol [42]. As intracellular cholesterol is necessary for en-
hanced CMV virus production and effective entry into other
cells [43, 44], a reduction in cellular cholesterol uptake by the
host cell could explain the association between elevated cho-
lesterol and EM accumulation seen here [42]. This does not,
however, rule out the possibility of CMV-induced alterations
in systemic lipid and glucose levels.
The current finding that CMV+ individuals with higher
levels of HbA1c and CVD risk factors (cholesterol and triacyl-
glycerol) had elevated dCTLs provides further evidence for a
common impact of both CMV [30, 45, 46] and dysregulated
glucose metabolism [47] on cardiac health. Consistent with this
notion, studies have reported associations among circulating
dCTL, CMV-specific T cell responses and increased CVD risk
factors, such as heart valve calcification, carotid artery thickness
and increased BP [48–50]. Taken together, these findings sup-
port the hypothesis proposed by Simanek and colleagues [32]
that CMVinfection and inflammation partially impact mortality
risk via their combined contribution to other CVD risk factors,
and further suggest dysregulated glucose metabolism and in-
creased dCTLs as additional mechanisms.
There are a number of limitations with the current study that
should be acknowledged. First, the low number of diabetic
participants precluded their inclusion as a separate group; com-
parisons were instead performed between normoglycaemic and
a merged hyperglycaemic group. Information about whether
these participants had type 1 or type 2 diabetes was also unavail-
able; however, in the general population, type 1 diabetes repre-
sents only 5–10% of the diabetes cases [27]. Likewise, clinically
relevant markers of immunosenescence (e.g. short telomere
length) are observed even at the early stages of glucose dysreg-
ulation [4, 20], and the associations found in hyperglycaemic
individuals were not altered by removal of the diabetic group
from the analyses. Second, there was no direct measure of sub-
sequent CMVreactivation. Nevertheless, the selective EMRAT
cell accumulation is almost exclusively associated with CMV
infection, and there is a strong empirical basis to suggest that
these associations reflect CMVactivity [2, 6, 9]. However, future
studies should include more direct measures of CMV reactiva-
tion (e.g. quantitative CMV-specific antibody levels) for com-
parison. Finally, because of the cross-sectional nature of the
study, we are unable to discern cause–effect relationships.
Given the complex interplay between components of the im-
mune system, metabolic factors, CMV and ageing, as well as
the contribution of potential intermediaries such as oxidative
stress and inflammation to these processes, bidirectional or cy-
clical relationships between these factors cannot be ruled out.
In conclusion, we observed associations between measures
of glucose metabolism (i.e. HbA1c level and diabetic status),
dyslipidaemia (total cholesterol and triacylglycerol levels) and
dCTL subsets in CMV+ individuals. These associations with
HbA1c level withstood adjustment for demographic, SES and
lifestyle factors known to impact both CMV infection and
glucose metabolism, thus demonstrating a robust association.
Overall, it appears that these metabolic factors act reciprocally
with CMV to amplify the accumulation of EM and EMRA
CD8+ T cells, and represent potentially biologically relevant
pathways underlying the CMV-induced acceleration of
immunosenescence. These data also highlight CMV and
dCTL accumulation as a potentially overlooked mechanism
underlying the associations of hyperglycaemia and diabetes
with impaired immunity. These links to immunosenescence
are particularly relevant in the context of increased incidence
of type 2 diabetes and an associated defective viral response in
an ageing population.
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